nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—CYP2C9—brain cancer	0.597	1	CbGaD
Rosiglitazone—CYP2D6—Lomustine—brain cancer	0.0658	0.245	CbGbCtD
Rosiglitazone—CYP1A2—Carmustine—brain cancer	0.0651	0.243	CbGbCtD
Rosiglitazone—CYP2D6—Hydroxyurea—brain cancer	0.0498	0.186	CbGbCtD
Rosiglitazone—PTGS1—Etoposide—brain cancer	0.0432	0.161	CbGbCtD
Rosiglitazone—CYP2C8—Etoposide—brain cancer	0.0249	0.093	CbGbCtD
Rosiglitazone—CYP1A2—Etoposide—brain cancer	0.0193	0.072	CbGbCtD
Rosiglitazone—Pioglitazone—CYP2C9—brain cancer	0.0034	1	CrCbGaD
Rosiglitazone—PPARG—Teniposide—Etoposide—brain cancer	0.00281	1	CbGdCrCtD
Rosiglitazone—CYP2A6—CYP2E1 reactions—CYP2C9—brain cancer	0.00199	0.0371	CbGpPWpGaD
Rosiglitazone—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—CYP2C9—brain cancer	0.00195	0.0364	CbGpPWpGaD
Rosiglitazone—Pleural effusion—Procarbazine—brain cancer	0.00182	0.0322	CcSEcCtD
Rosiglitazone—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00175	0.0327	CbGpPWpGaD
Rosiglitazone—PTGS1—Prostaglandin Synthesis and Regulation—S100A6—brain cancer	0.00164	0.0306	CbGpPWpGaD
Rosiglitazone—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.0016	0.0298	CbGpPWpGaD
Rosiglitazone—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00156	0.0292	CbGpPWpGaD
Rosiglitazone—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00142	0.0266	CbGpPWpGaD
Rosiglitazone—Visual acuity reduced—Temozolomide—brain cancer	0.00142	0.0251	CcSEcCtD
Rosiglitazone—CYP2C8—CYP2E1 reactions—CYP2C9—brain cancer	0.00136	0.0254	CbGpPWpGaD
Rosiglitazone—CYP2A6—Xenobiotics—CYP2C9—brain cancer	0.00123	0.023	CbGpPWpGaD
Rosiglitazone—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00122	0.0228	CbGpPWpGaD
Rosiglitazone—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00122	0.0227	CbGpPWpGaD
Rosiglitazone—CYP2C19—CYP2E1 reactions—CYP2C9—brain cancer	0.00121	0.0226	CbGpPWpGaD
Rosiglitazone—CYP2A6—Tamoxifen metabolism—CYP2C9—brain cancer	0.00119	0.0221	CbGpPWpGaD
Rosiglitazone—PPARG—endothelium—brain cancer	0.00117	0.0629	CbGeAlD
Rosiglitazone—Hepatic function abnormal—Procarbazine—brain cancer	0.00116	0.0205	CcSEcCtD
Rosiglitazone—Hepatic enzyme increased—Hydroxyurea—brain cancer	0.00114	0.0202	CcSEcCtD
Rosiglitazone—PTGS1—Prostaglandin Synthesis and Regulation—S100A10—brain cancer	0.00114	0.0212	CbGpPWpGaD
Rosiglitazone—CYP2D6—CYP2E1 reactions—CYP2C9—brain cancer	0.00112	0.0208	CbGpPWpGaD
Rosiglitazone—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00111	0.0207	CbGpPWpGaD
Rosiglitazone—PPARG—blood vessel—brain cancer	0.00108	0.058	CbGeAlD
Rosiglitazone—ACSL4—gonad—brain cancer	0.00097	0.0522	CbGeAlD
Rosiglitazone—Pulmonary oedema—Hydroxyurea—brain cancer	0.000963	0.017	CcSEcCtD
Rosiglitazone—ACSL4—pituitary gland—brain cancer	0.000946	0.0509	CbGeAlD
Rosiglitazone—Hyperbilirubinaemia—Temozolomide—brain cancer	0.000929	0.0164	CcSEcCtD
Rosiglitazone—ACSL4—medulla oblongata—brain cancer	0.000913	0.0491	CbGeAlD
Rosiglitazone—Hepatic enzyme increased—Temozolomide—brain cancer	0.000893	0.0158	CcSEcCtD
Rosiglitazone—Infection—Carboplatin—brain cancer	0.000892	0.0158	CcSEcCtD
Rosiglitazone—Hepatic failure—Hydroxyurea—brain cancer	0.000874	0.0154	CcSEcCtD
Rosiglitazone—Leukopenia—Lomustine—brain cancer	0.000861	0.0152	CcSEcCtD
Rosiglitazone—CYP2A6—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000847	0.0158	CbGpPWpGaD
Rosiglitazone—CYP2C8—Xenobiotics—CYP2C9—brain cancer	0.000842	0.0157	CbGpPWpGaD
Rosiglitazone—ACSL4—midbrain—brain cancer	0.000834	0.0449	CbGeAlD
Rosiglitazone—ACSL4—spinal cord—brain cancer	0.000814	0.0438	CbGeAlD
Rosiglitazone—CYP2C8—Tamoxifen metabolism—CYP2C9—brain cancer	0.00081	0.0151	CbGpPWpGaD
Rosiglitazone—Infection—Lomustine—brain cancer	0.00078	0.0138	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Lomustine—brain cancer	0.000769	0.0136	CcSEcCtD
Rosiglitazone—CYP2C19—Xenobiotics—CYP2C9—brain cancer	0.000752	0.014	CbGpPWpGaD
Rosiglitazone—ACSL4—endocrine gland—brain cancer	0.000733	0.0395	CbGeAlD
Rosiglitazone—Diabetes mellitus—Carmustine—brain cancer	0.00073	0.0129	CcSEcCtD
Rosiglitazone—PTGS1—ganglion—brain cancer	0.000724	0.039	CbGeAlD
Rosiglitazone—ACSL4—head—brain cancer	0.000723	0.039	CbGeAlD
Rosiglitazone—CYP2C19—Tamoxifen metabolism—CYP2C9—brain cancer	0.000723	0.0135	CbGpPWpGaD
Rosiglitazone—CYP2D6—Xenobiotics—CYP2C9—brain cancer	0.000691	0.0129	CbGpPWpGaD
Rosiglitazone—Hepatic failure—Temozolomide—brain cancer	0.000682	0.0121	CcSEcCtD
Rosiglitazone—CYP2D6—Tamoxifen metabolism—CYP2C9—brain cancer	0.000665	0.0124	CbGpPWpGaD
Rosiglitazone—ACSL4—central nervous system—brain cancer	0.00066	0.0356	CbGeAlD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—SMARCB1—brain cancer	0.000655	0.0122	CbGpPWpGaD
Rosiglitazone—ACSL4—cerebellum—brain cancer	0.000645	0.0348	CbGeAlD
Rosiglitazone—PTGS1—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000626	0.0117	CbGpPWpGaD
Rosiglitazone—PTGS1—endothelium—brain cancer	0.000625	0.0336	CbGeAlD
Rosiglitazone—Weight increased—Hydroxyurea—brain cancer	0.000617	0.0109	CcSEcCtD
Rosiglitazone—CYP1A2—Xenobiotics—CYP2C9—brain cancer	0.000586	0.0109	CbGpPWpGaD
Rosiglitazone—PTGS1—blood vessel—brain cancer	0.000576	0.031	CbGeAlD
Rosiglitazone—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000572	0.0101	CcSEcCtD
Rosiglitazone—Anaemia—Procarbazine—brain cancer	0.000565	0.00998	CcSEcCtD
Rosiglitazone—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.000563	0.0105	CbGpPWpGaD
Rosiglitazone—Leukopenia—Procarbazine—brain cancer	0.000547	0.00966	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Etoposide—brain cancer	0.000541	0.00956	CcSEcCtD
Rosiglitazone—Hypertension—Procarbazine—brain cancer	0.000527	0.00932	CcSEcCtD
Rosiglitazone—ACSL4—brain—brain cancer	0.000524	0.0282	CbGeAlD
Rosiglitazone—Myalgia—Procarbazine—brain cancer	0.00052	0.00919	CcSEcCtD
Rosiglitazone—Arthralgia—Procarbazine—brain cancer	0.00052	0.00919	CcSEcCtD
Rosiglitazone—PPARG—Transcription factor regulation in adipogenesis—IRS2—brain cancer	0.000518	0.00966	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Irinotecan Pathway—APC—brain cancer	0.000517	0.00965	CbGpPWpGaD
Rosiglitazone—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000516	0.00963	CbGpPWpGaD
Rosiglitazone—PPARG—Nuclear Receptors—ESR2—brain cancer	0.000515	0.00961	CbGpPWpGaD
Rosiglitazone—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000512	0.00956	CbGpPWpGaD
Rosiglitazone—CYP2A6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000505	0.00943	CbGpPWpGaD
Rosiglitazone—Cardiac failure—Etoposide—brain cancer	0.000503	0.00889	CcSEcCtD
Rosiglitazone—Oedema—Procarbazine—brain cancer	0.000499	0.00881	CcSEcCtD
Rosiglitazone—Infection—Procarbazine—brain cancer	0.000495	0.00875	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Carmustine—brain cancer	0.000495	0.00874	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Temozolomide—brain cancer	0.000493	0.00871	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Procarbazine—brain cancer	0.000488	0.00863	CcSEcCtD
Rosiglitazone—Weight increased—Temozolomide—brain cancer	0.000482	0.00852	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Temozolomide—brain cancer	0.000478	0.00845	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000469	0.00828	CcSEcCtD
Rosiglitazone—Nausea—Lomustine—brain cancer	0.000466	0.00824	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000454	0.00803	CcSEcCtD
Rosiglitazone—CYP2D6—hindbrain—brain cancer	0.000452	0.0243	CbGeAlD
Rosiglitazone—Hepatobiliary disease—Temozolomide—brain cancer	0.000447	0.0079	CcSEcCtD
Rosiglitazone—Sinusitis—Temozolomide—brain cancer	0.000443	0.00784	CcSEcCtD
Rosiglitazone—PTGS1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000439	0.00819	CbGpPWpGaD
Rosiglitazone—Anaemia—Hydroxyurea—brain cancer	0.000437	0.00772	CcSEcCtD
Rosiglitazone—Oedema peripheral—Carmustine—brain cancer	0.000432	0.00764	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Carmustine—brain cancer	0.000431	0.00762	CcSEcCtD
Rosiglitazone—Fatigue—Procarbazine—brain cancer	0.00043	0.0076	CcSEcCtD
Rosiglitazone—Constipation—Procarbazine—brain cancer	0.000426	0.00753	CcSEcCtD
Rosiglitazone—Hepatitis—Temozolomide—brain cancer	0.000424	0.0075	CcSEcCtD
Rosiglitazone—PPARG—Wnt Signaling Pathway Netpath—CDK6—brain cancer	0.000423	0.0079	CbGpPWpGaD
Rosiglitazone—Leukopenia—Hydroxyurea—brain cancer	0.000423	0.00748	CcSEcCtD
Rosiglitazone—Oedema peripheral—Temozolomide—brain cancer	0.000418	0.00739	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Temozolomide—brain cancer	0.000417	0.00737	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000416	0.00777	CbGpPWpGaD
Rosiglitazone—CYP2A6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000415	0.00775	CbGpPWpGaD
Rosiglitazone—Eye disorder—Carmustine—brain cancer	0.00041	0.00725	CcSEcCtD
Rosiglitazone—PPARG—Nuclear Receptor transcription pathway—ESR2—brain cancer	0.000407	0.0076	CbGpPWpGaD
Rosiglitazone—CYP2C8—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000405	0.00755	CbGpPWpGaD
Rosiglitazone—Erythema multiforme—Temozolomide—brain cancer	0.000401	0.00709	CcSEcCtD
Rosiglitazone—Eye disorder—Temozolomide—brain cancer	0.000396	0.00701	CcSEcCtD
Rosiglitazone—Urticaria—Procarbazine—brain cancer	0.000396	0.007	CcSEcCtD
Rosiglitazone—Cardiac disorder—Temozolomide—brain cancer	0.000394	0.00696	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—SKP2—brain cancer	0.000392	0.00732	CbGpPWpGaD
Rosiglitazone—Oedema—Hydroxyurea—brain cancer	0.000386	0.00682	CcSEcCtD
Rosiglitazone—Infection—Hydroxyurea—brain cancer	0.000383	0.00677	CcSEcCtD
Rosiglitazone—Immune system disorder—Temozolomide—brain cancer	0.000383	0.00677	CcSEcCtD
Rosiglitazone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000383	0.00715	CbGpPWpGaD
Rosiglitazone—SLCO1B1—endocrine gland—brain cancer	0.000382	0.0206	CbGeAlD
Rosiglitazone—Malnutrition—Carmustine—brain cancer	0.000382	0.00675	CcSEcCtD
Rosiglitazone—Nervous system disorder—Hydroxyurea—brain cancer	0.000378	0.00669	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Hydroxyurea—brain cancer	0.000378	0.00668	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000375	0.00663	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Etoposide—brain cancer	0.000373	0.00659	CcSEcCtD
Rosiglitazone—Myocardial infarction—Etoposide—brain cancer	0.000371	0.00655	CcSEcCtD
Rosiglitazone—Back pain—Carmustine—brain cancer	0.00037	0.00653	CcSEcCtD
Rosiglitazone—Malnutrition—Temozolomide—brain cancer	0.000369	0.00653	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—DNMT1—brain cancer	0.000369	0.00689	CbGpPWpGaD
Rosiglitazone—CYP2C19—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000361	0.00674	CbGpPWpGaD
Rosiglitazone—Asthenia—Procarbazine—brain cancer	0.000358	0.00632	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Etoposide—brain cancer	0.000358	0.00632	CcSEcCtD
Rosiglitazone—Back pain—Temozolomide—brain cancer	0.000357	0.00631	CcSEcCtD
Rosiglitazone—Anaemia—Carmustine—brain cancer	0.000353	0.00624	CcSEcCtD
Rosiglitazone—Pruritus—Procarbazine—brain cancer	0.000353	0.00623	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—CDK6—brain cancer	0.00035	0.00653	CbGpPWpGaD
Rosiglitazone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00035	0.00653	CbGpPWpGaD
Rosiglitazone—CYP2C8—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000345	0.00644	CbGpPWpGaD
Rosiglitazone—Leukopenia—Carmustine—brain cancer	0.000342	0.00605	CcSEcCtD
Rosiglitazone—Anaemia—Temozolomide—brain cancer	0.000341	0.00603	CcSEcCtD
Rosiglitazone—Diarrhoea—Procarbazine—brain cancer	0.000341	0.00603	CcSEcCtD
Rosiglitazone—CYP2A6—cerebellum—brain cancer	0.000341	0.0184	CbGeAlD
Rosiglitazone—Angioedema—Temozolomide—brain cancer	0.000337	0.00596	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000333	0.00589	CcSEcCtD
Rosiglitazone—Fatigue—Hydroxyurea—brain cancer	0.000333	0.00588	CcSEcCtD
Rosiglitazone—Leukopenia—Temozolomide—brain cancer	0.000331	0.00584	CcSEcCtD
Rosiglitazone—Hypertension—Carmustine—brain cancer	0.00033	0.00583	CcSEcCtD
Rosiglitazone—Constipation—Hydroxyurea—brain cancer	0.00033	0.00583	CcSEcCtD
Rosiglitazone—PPARG—endocrine gland—brain cancer	0.00033	0.0178	CbGeAlD
Rosiglitazone—Dizziness—Procarbazine—brain cancer	0.00033	0.00583	CcSEcCtD
Rosiglitazone—PPARG—Circadian rythm related genes—NTRK3—brain cancer	0.00033	0.00615	CbGpPWpGaD
Rosiglitazone—PPARG—head—brain cancer	0.000325	0.0175	CbGeAlD
Rosiglitazone—Myalgia—Carmustine—brain cancer	0.000325	0.00575	CcSEcCtD
Rosiglitazone—Erythema multiforme—Etoposide—brain cancer	0.000321	0.00567	CcSEcCtD
Rosiglitazone—Hypertension—Temozolomide—brain cancer	0.000319	0.00564	CcSEcCtD
Rosiglitazone—Eye disorder—Etoposide—brain cancer	0.000317	0.00561	CcSEcCtD
Rosiglitazone—Cardiac disorder—Etoposide—brain cancer	0.000315	0.00557	CcSEcCtD
Rosiglitazone—Arthralgia—Temozolomide—brain cancer	0.000314	0.00556	CcSEcCtD
Rosiglitazone—Myalgia—Temozolomide—brain cancer	0.000314	0.00556	CcSEcCtD
Rosiglitazone—Rash—Procarbazine—brain cancer	0.000314	0.00556	CcSEcCtD
Rosiglitazone—Dermatitis—Procarbazine—brain cancer	0.000314	0.00555	CcSEcCtD
Rosiglitazone—Headache—Procarbazine—brain cancer	0.000312	0.00552	CcSEcCtD
Rosiglitazone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000312	0.00583	CbGpPWpGaD
Rosiglitazone—Oedema—Carmustine—brain cancer	0.000312	0.00551	CcSEcCtD
Rosiglitazone—Infection—Carmustine—brain cancer	0.00031	0.00548	CcSEcCtD
Rosiglitazone—CYP2C19—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000308	0.00575	CbGpPWpGaD
Rosiglitazone—Immune system disorder—Etoposide—brain cancer	0.000307	0.00542	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Carmustine—brain cancer	0.000305	0.0054	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000304	0.00568	CbGpPWpGaD
Rosiglitazone—Oedema—Temozolomide—brain cancer	0.000301	0.00533	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Temozolomide—brain cancer	0.000301	0.00533	CcSEcCtD
Rosiglitazone—Infection—Temozolomide—brain cancer	0.000299	0.00529	CcSEcCtD
Rosiglitazone—PPARG—central nervous system—brain cancer	0.000297	0.016	CbGeAlD
Rosiglitazone—Nausea—Procarbazine—brain cancer	0.000296	0.00523	CcSEcCtD
Rosiglitazone—Nervous system disorder—Temozolomide—brain cancer	0.000296	0.00522	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Temozolomide—brain cancer	0.000295	0.00522	CcSEcCtD
Rosiglitazone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000287	0.00536	CbGpPWpGaD
Rosiglitazone—Back pain—Etoposide—brain cancer	0.000286	0.00505	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Carmustine—brain cancer	0.000284	0.00502	CcSEcCtD
Rosiglitazone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000283	0.00529	CbGpPWpGaD
Rosiglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000283	0.00529	CbGpPWpGaD
Rosiglitazone—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000281	0.00525	CbGpPWpGaD
Rosiglitazone—CYP2C8—pituitary gland—brain cancer	0.000281	0.0151	CbGeAlD
Rosiglitazone—PTGS1—telencephalon—brain cancer	0.000279	0.015	CbGeAlD
Rosiglitazone—CYP2A6—brain—brain cancer	0.000277	0.0149	CbGeAlD
Rosiglitazone—Asthenia—Hydroxyurea—brain cancer	0.000277	0.00489	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000275	0.00485	CcSEcCtD
Rosiglitazone—Anaemia—Etoposide—brain cancer	0.000273	0.00483	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Carmustine—brain cancer	0.000269	0.00476	CcSEcCtD
Rosiglitazone—Constipation—Carmustine—brain cancer	0.000267	0.00471	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—SIRT1—brain cancer	0.000267	0.00498	CbGpPWpGaD
Rosiglitazone—Leukopenia—Etoposide—brain cancer	0.000265	0.00467	CcSEcCtD
Rosiglitazone—Diarrhoea—Hydroxyurea—brain cancer	0.000264	0.00467	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—CCNE1—brain cancer	0.000263	0.00492	CbGpPWpGaD
Rosiglitazone—Gastrointestinal disorder—Temozolomide—brain cancer	0.00026	0.0046	CcSEcCtD
Rosiglitazone—Fatigue—Temozolomide—brain cancer	0.00026	0.00459	CcSEcCtD
Rosiglitazone—CYP2D6—brainstem—brain cancer	0.000259	0.0139	CbGeAlD
Rosiglitazone—Constipation—Temozolomide—brain cancer	0.000258	0.00456	CcSEcCtD
Rosiglitazone—PPARG—SREBP signalling—SIRT1—brain cancer	0.000257	0.0048	CbGpPWpGaD
Rosiglitazone—Hypertension—Etoposide—brain cancer	0.000255	0.00451	CcSEcCtD
Rosiglitazone—Dizziness—Hydroxyurea—brain cancer	0.000255	0.00451	CcSEcCtD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—SIRT1—brain cancer	0.000254	0.00475	CbGpPWpGaD
Rosiglitazone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000253	0.00472	CbGpPWpGaD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—brain cancer	0.000252	0.0047	CbGpPWpGaD
Rosiglitazone—CYP2C19—endocrine gland—brain cancer	0.000249	0.0134	CbGeAlD
Rosiglitazone—Rash—Hydroxyurea—brain cancer	0.000243	0.0043	CcSEcCtD
Rosiglitazone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000243	0.00454	CbGpPWpGaD
Rosiglitazone—Dermatitis—Hydroxyurea—brain cancer	0.000243	0.0043	CcSEcCtD
Rosiglitazone—Headache—Hydroxyurea—brain cancer	0.000242	0.00427	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Etoposide—brain cancer	0.000241	0.00426	CcSEcCtD
Rosiglitazone—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00024	0.00448	CbGpPWpGaD
Rosiglitazone—Infection—Etoposide—brain cancer	0.00024	0.00423	CcSEcCtD
Rosiglitazone—Urticaria—Temozolomide—brain cancer	0.000239	0.00423	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Etoposide—brain cancer	0.000236	0.00417	CcSEcCtD
Rosiglitazone—PPARG—brain—brain cancer	0.000236	0.0127	CbGeAlD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	0.000234	0.00436	CbGpPWpGaD
Rosiglitazone—PTGS1—Biological oxidations—CYP2C9—brain cancer	0.000233	0.00435	CbGpPWpGaD
Rosiglitazone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000233	0.00434	CbGpPWpGaD
Rosiglitazone—PPARG—Wnt Signaling Pathway Netpath—APC—brain cancer	0.00023	0.00429	CbGpPWpGaD
Rosiglitazone—CYP2D6—telencephalon—brain cancer	0.00023	0.0124	CbGeAlD
Rosiglitazone—Nausea—Hydroxyurea—brain cancer	0.000229	0.00405	CcSEcCtD
Rosiglitazone—PTGS1—pituitary gland—brain cancer	0.000228	0.0122	CbGeAlD
Rosiglitazone—Asthenia—Carmustine—brain cancer	0.000224	0.00395	CcSEcCtD
Rosiglitazone—ALB—brain—brain cancer	0.000221	0.0119	CbGeAlD
Rosiglitazone—CYP2A6—Biological oxidations—CYP2C9—brain cancer	0.00022	0.00411	CbGpPWpGaD
Rosiglitazone—CYP2C8—endocrine gland—brain cancer	0.000217	0.0117	CbGeAlD
Rosiglitazone—Asthenia—Temozolomide—brain cancer	0.000216	0.00382	CcSEcCtD
Rosiglitazone—Diarrhoea—Carmustine—brain cancer	0.000213	0.00377	CcSEcCtD
Rosiglitazone—Pruritus—Temozolomide—brain cancer	0.000213	0.00377	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Etoposide—brain cancer	0.000208	0.00368	CcSEcCtD
Rosiglitazone—Fatigue—Etoposide—brain cancer	0.000208	0.00367	CcSEcCtD
Rosiglitazone—Dizziness—Carmustine—brain cancer	0.000206	0.00365	CcSEcCtD
Rosiglitazone—Constipation—Etoposide—brain cancer	0.000206	0.00365	CcSEcCtD
Rosiglitazone—Diarrhoea—Temozolomide—brain cancer	0.000206	0.00364	CcSEcCtD
Rosiglitazone—CYP1A2—endocrine gland—brain cancer	0.000203	0.011	CbGeAlD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—CDK4—brain cancer	0.000202	0.00376	CbGpPWpGaD
Rosiglitazone—Dizziness—Temozolomide—brain cancer	0.000199	0.00352	CcSEcCtD
Rosiglitazone—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000197	0.00368	CbGpPWpGaD
Rosiglitazone—Rash—Carmustine—brain cancer	0.000197	0.00348	CcSEcCtD
Rosiglitazone—Dermatitis—Carmustine—brain cancer	0.000196	0.00347	CcSEcCtD
Rosiglitazone—PTGS1—spinal cord—brain cancer	0.000196	0.0105	CbGeAlD
Rosiglitazone—Headache—Carmustine—brain cancer	0.000195	0.00345	CcSEcCtD
Rosiglitazone—CYP2C9—endocrine gland—brain cancer	0.000193	0.0104	CbGeAlD
Rosiglitazone—Urticaria—Etoposide—brain cancer	0.000192	0.00339	CcSEcCtD
Rosiglitazone—Rash—Temozolomide—brain cancer	0.00019	0.00336	CcSEcCtD
Rosiglitazone—Dermatitis—Temozolomide—brain cancer	0.00019	0.00336	CcSEcCtD
Rosiglitazone—Headache—Temozolomide—brain cancer	0.000189	0.00334	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism—CYP2C9—brain cancer	0.000185	0.00346	CbGpPWpGaD
Rosiglitazone—Nausea—Carmustine—brain cancer	0.000185	0.00327	CcSEcCtD
Rosiglitazone—Nausea—Temozolomide—brain cancer	0.000179	0.00316	CcSEcCtD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—CDK4—brain cancer	0.000178	0.00333	CbGpPWpGaD
Rosiglitazone—PTGS1—endocrine gland—brain cancer	0.000176	0.00949	CbGeAlD
Rosiglitazone—PTGS1—head—brain cancer	0.000174	0.00937	CbGeAlD
Rosiglitazone—Asthenia—Etoposide—brain cancer	0.000173	0.00306	CcSEcCtD
Rosiglitazone—Pruritus—Etoposide—brain cancer	0.000171	0.00302	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—brain cancer	0.000167	0.00311	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Etoposide—brain cancer	0.000165	0.00292	CcSEcCtD
Rosiglitazone—Dizziness—Etoposide—brain cancer	0.00016	0.00282	CcSEcCtD
Rosiglitazone—PTGS1—central nervous system—brain cancer	0.000159	0.00855	CbGeAlD
Rosiglitazone—ACSL4—Metabolism—BSG—brain cancer	0.000158	0.00294	CbGpPWpGaD
Rosiglitazone—PPARG—Wnt Signaling Pathway Netpath—CCND1—brain cancer	0.000158	0.00294	CbGpPWpGaD
Rosiglitazone—PPARG—Wnt Signaling Pathway Netpath—CTNNB1—brain cancer	0.000156	0.00291	CbGpPWpGaD
Rosiglitazone—CYP2C8—brain—brain cancer	0.000155	0.00837	CbGeAlD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—MPL—brain cancer	0.000154	0.00288	CbGpPWpGaD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—CDKN2A—brain cancer	0.000154	0.00288	CbGpPWpGaD
Rosiglitazone—Rash—Etoposide—brain cancer	0.000152	0.00269	CcSEcCtD
Rosiglitazone—Dermatitis—Etoposide—brain cancer	0.000152	0.00269	CcSEcCtD
Rosiglitazone—Headache—Etoposide—brain cancer	0.000151	0.00267	CcSEcCtD
Rosiglitazone—CYP2C8—Biological oxidations—CYP2C9—brain cancer	0.000151	0.00281	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metapathway biotransformation—CYP2C9—brain cancer	0.000149	0.00277	CbGpPWpGaD
Rosiglitazone—CYP2D6—endocrine gland—brain cancer	0.000145	0.0078	CbGeAlD
Rosiglitazone—Nausea—Etoposide—brain cancer	0.000143	0.00253	CcSEcCtD
Rosiglitazone—CYP2D6—head—brain cancer	0.000143	0.0077	CbGeAlD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—SOD2—brain cancer	0.000143	0.00267	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—SOD2—brain cancer	0.000142	0.00265	CbGpPWpGaD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—RELA—brain cancer	0.000142	0.00264	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—IDH1—brain cancer	0.000136	0.00253	CbGpPWpGaD
Rosiglitazone—CYP2C19—Biological oxidations—CYP2C9—brain cancer	0.000134	0.00251	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metapathway biotransformation—CYP2C9—brain cancer	0.000133	0.00247	CbGpPWpGaD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—RELA—brain cancer	0.000131	0.00245	CbGpPWpGaD
Rosiglitazone—CYP2D6—central nervous system—brain cancer	0.000131	0.00703	CbGeAlD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—CCND1—brain cancer	0.00013	0.00243	CbGpPWpGaD
Rosiglitazone—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	0.00013	0.00242	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000128	0.00239	CbGpPWpGaD
Rosiglitazone—CYP2D6—cerebellum—brain cancer	0.000128	0.00687	CbGeAlD
Rosiglitazone—PPARG—Wnt Signaling Pathway Netpath—MYC—brain cancer	0.000126	0.00236	CbGpPWpGaD
Rosiglitazone—PTGS1—brain—brain cancer	0.000126	0.00679	CbGeAlD
Rosiglitazone—PPARG—Adipogenesis—IRS2—brain cancer	0.000125	0.00233	CbGpPWpGaD
Rosiglitazone—CYP2D6—Biological oxidations—CYP2C9—brain cancer	0.000124	0.00231	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	0.000122	0.00228	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—SOD2—brain cancer	0.000115	0.00216	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000115	0.00216	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	0.00011	0.00206	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—SIRT1—brain cancer	0.000109	0.00204	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000108	0.00202	CbGpPWpGaD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—STAT3—brain cancer	0.000107	0.002	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—ENO2—brain cancer	0.000107	0.002	CbGpPWpGaD
Rosiglitazone—CYP1A2—Biological oxidations—CYP2C9—brain cancer	0.000105	0.00195	CbGpPWpGaD
Rosiglitazone—CYP2D6—brain—brain cancer	0.000104	0.00558	CbGeAlD
Rosiglitazone—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	0.000103	0.00193	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000101	0.00188	CbGpPWpGaD
Rosiglitazone—CYP2A6—Fluoropyrimidine Activity—TP53—brain cancer	9.9e-05	0.00185	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—IDH1—brain cancer	9.34e-05	0.00174	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—SOD2—brain cancer	9.17e-05	0.00171	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	8.95e-05	0.00167	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—CDK4—brain cancer	8.28e-05	0.00154	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—RELA—brain cancer	8.26e-05	0.00154	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—RELA—brain cancer	8.2e-05	0.00153	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—TRPC6—brain cancer	7.98e-05	0.00149	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—MPL—brain cancer	7.95e-05	0.00148	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—S100A10—brain cancer	7.62e-05	0.00142	CbGpPWpGaD
Rosiglitazone—PPARG—Adipogenesis—CTNNB1—brain cancer	7.5e-05	0.0014	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	7.36e-05	0.00137	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—ESR2—brain cancer	7.03e-05	0.00131	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—TRPC6—brain cancer	6.83e-05	0.00127	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—RELA—brain cancer	6.67e-05	0.00125	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—NOTCH2—brain cancer	6.66e-05	0.00124	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—S100A10—brain cancer	6.6e-05	0.00123	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	6.55e-05	0.00122	CbGpPWpGaD
Rosiglitazone—PPARG—Adipogenesis—STAT3—brain cancer	6.54e-05	0.00122	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	6.23e-05	0.00116	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—IL2—brain cancer	6.01e-05	0.00112	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	5.78e-05	0.00108	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	5.75e-05	0.00107	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CYP2C9—brain cancer	5.69e-05	0.00106	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	5.61e-05	0.00105	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—BSG—brain cancer	5.37e-05	0.001	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—TRPC6—brain cancer	5.33e-05	0.000995	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—RELA—brain cancer	5.3e-05	0.00099	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	5.16e-05	0.000963	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—HES1—brain cancer	5.14e-05	0.000959	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—VAV1—brain cancer	5.12e-05	0.000955	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—PIK3CG—brain cancer	4.92e-05	0.000918	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—BSG—brain cancer	4.84e-05	0.000903	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	4.77e-05	0.00089	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CYP2C9—brain cancer	4.48e-05	0.000836	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	4.39e-05	0.000819	CbGpPWpGaD
Rosiglitazone—ALB—Platelet degranulation—VEGFA—brain cancer	4.38e-05	0.000818	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	4.29e-05	0.000801	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	4.29e-05	0.000801	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	4.23e-05	0.000789	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	4.2e-05	0.000785	CbGpPWpGaD
Rosiglitazone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	4.17e-05	0.000779	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—IDH1—brain cancer	4.16e-05	0.000777	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—CDK4—brain cancer	4.03e-05	0.000752	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	4.02e-05	0.000751	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CYP2C9—brain cancer	3.99e-05	0.000744	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—TP53—brain cancer	3.86e-05	0.00072	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—BSG—brain cancer	3.81e-05	0.000711	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.77e-05	0.000704	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—DNMT1—brain cancer	3.77e-05	0.000704	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CYP2C9—brain cancer	3.77e-05	0.000704	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—TP53—brain cancer	3.52e-05	0.000657	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TRPC6—brain cancer	3.52e-05	0.000657	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.44e-05	0.000642	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—BSG—brain cancer	3.39e-05	0.000633	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.39e-05	0.000632	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—ESR2—brain cancer	3.39e-05	0.000632	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—ENO2—brain cancer	3.29e-05	0.000614	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—IDH1—brain cancer	3.28e-05	0.000612	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	3.25e-05	0.000606	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—NOTCH2—brain cancer	3.21e-05	0.000598	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—BSG—brain cancer	3.21e-05	0.000598	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	3.05e-05	0.000569	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—RELA—brain cancer	2.96e-05	0.000553	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—ERBB2—brain cancer	2.95e-05	0.00055	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.94e-05	0.000549	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—IDH1—brain cancer	2.92e-05	0.000544	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—IDH1—brain cancer	2.76e-05	0.000515	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—SIRT1—brain cancer	2.73e-05	0.000509	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.67e-05	0.000498	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—VAV1—brain cancer	2.64e-05	0.000492	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—ENO2—brain cancer	2.59e-05	0.000483	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—CTNNB1—brain cancer	2.58e-05	0.000481	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP2C9—brain cancer	2.58e-05	0.000481	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP2C9—brain cancer	2.56e-05	0.000478	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.37e-05	0.000443	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—ENO2—brain cancer	2.3e-05	0.00043	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP2C9—brain cancer	2.3e-05	0.000429	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	2.29e-05	0.000427	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—VEGFA—brain cancer	2.27e-05	0.000424	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—STAT3—brain cancer	2.25e-05	0.000419	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—MYC—brain cancer	2.22e-05	0.000414	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—BSG—brain cancer	2.19e-05	0.000409	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—ENO2—brain cancer	2.18e-05	0.000407	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—BSG—brain cancer	2.18e-05	0.000406	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP2C9—brain cancer	2.11e-05	0.000395	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—EGFR—brain cancer	2.04e-05	0.000381	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—BSG—brain cancer	1.95e-05	0.000365	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	1.94e-05	0.000363	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—IDH1—brain cancer	1.88e-05	0.000351	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—IDH1—brain cancer	1.87e-05	0.000349	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—BSG—brain cancer	1.8e-05	0.000336	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP2C9—brain cancer	1.79e-05	0.000334	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—BSG—brain cancer	1.78e-05	0.000333	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—IDH1—brain cancer	1.68e-05	0.000314	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CG—brain cancer	1.67e-05	0.000313	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—IDH1—brain cancer	1.55e-05	0.000289	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.53e-05	0.000286	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—IDH1—brain cancer	1.53e-05	0.000286	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.52e-05	0.000285	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—BSG—brain cancer	1.52e-05	0.000284	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CG—brain cancer	1.51e-05	0.000282	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ENO2—brain cancer	1.49e-05	0.000278	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ENO2—brain cancer	1.48e-05	0.000276	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.37e-05	0.000255	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ENO2—brain cancer	1.33e-05	0.000248	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—IDH1—brain cancer	1.31e-05	0.000244	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.25e-05	0.000233	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ENO2—brain cancer	1.22e-05	0.000228	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ENO2—brain cancer	1.21e-05	0.000226	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CG—brain cancer	1.19e-05	0.000222	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—IL2—brain cancer	1.18e-05	0.00022	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—MYC—brain cancer	1.07e-05	0.000199	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.07e-05	0.000199	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CG—brain cancer	1.06e-05	0.000197	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ENO2—brain cancer	1.04e-05	0.000193	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—VEGFA—brain cancer	1e-05	0.000187	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CG—brain cancer	1e-05	0.000187	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—brain cancer	7.57e-06	0.000141	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CG—brain cancer	6.83e-06	0.000127	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CG—brain cancer	6.79e-06	0.000127	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CG—brain cancer	6.09e-06	0.000114	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CG—brain cancer	5.61e-06	0.000105	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CG—brain cancer	5.56e-06	0.000104	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CG—brain cancer	4.75e-06	8.86e-05	CbGpPWpGaD
